IPSC · Century Therapeutics, Inc.
$2.11
+0.15 (+7.65%)
At close · Aug 19
Market Cap
$382.07M
Shares
181.08M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Carlo Rizzuto, Ph.D. | Board | Resigned | 2025-12-29 |
| Dr. Han Lee | directors of the Board | Appointed | 2025-12-09 |
| Dr. Martin Murphy | directors of the Board | Appointed | 2025-12-09 |
| Brent Pfeiffenberger | Chairman of the Board | Appointed | 2025-08-14 |
| Adrienne Farid, Ph.D. | Chief Development Officer | Terminated | 2025-07-07 |
| Morgan Conn, Ph.D. | Chief Financial Officer | Terminated | 2025-07-07 |
| Morgan Conn, Ph.D. | Chief Financial Officer | Appointed | 2024-09-26 |
| Michael C. Diem, M.D. | Chief Financial Officer | Resigned | 2024-01-19 |
| Brent Pfeiffenberger | member of the Board | Appointed | 2023-11-14 |
| Brent Pfeiffenberger | President and Chief Executive Officer | Appointed | 2023-11-14 |
| Michael Diem | Chief Financial Officer | Appointed | 2023-04-17 |
| Osvaldo Flores, Ph.D. | member of the Board of Directors | Resigned | 2023-04-17 |
| Gregory Russotti, Ph.D. | Interim President and Chief Executive Officer | Appointed | 2023-04-17 |
| Osvaldo Flores, Ph.D. | President and Chief Executive Officer | Resigned | 2023-04-17 |
| Timothy P. Walbert | Class II director | Appointed | 2022-10-03 |
| Daphne Quimi | Class I director | Appointed | 2022-10-03 |
| Eli Casdin | member of the board of directors | Resigned | 2022-10-03 |
Key facts
CIK
1850119
CUSIP
15673T100
13F (30d)
95 filings
95 filers
Visit website
Investor relations